Table 1.

Patient characteristics and response

Patient	Gender	PTV cm3	Metastatic Site	Progressed	Heng Score	Pathologic T Stage	Survival Time (Months)	Adjuvant Treatment
1	M	619	Adrenal	N	1	2A	42+	Clinical Trial agent, Adrenalectomy
2	F	891	Lung, psoas	N	4	NA	1	None
3	F	637	Lung	N	3	3A	4	None
5	M	355	Retroperitoneal	N	1	3A	4	None
6	F	501	Adrenal	Y	2	4	35+	Pazopanib, Bevacizumab alternating trial
7	M	129	Adrenal	Y	2	3A	20	RT, Pazopanib
9	M	37	Lung, Retroperitoneal	N	2	1A	24+	Sutent
10	F	664	Lung, Liver	N	1	3A	3	None
11	F	306	Bone	Y	1	NA	12	RT, Sutent, Nivolumab
12	F	105	Retroperitoneal	N	2	1	20+	Sutent, Nivolumab
13	F	891	Bone	Y	2	2	18+	Pazopanib, Nivolumab, RT, Sorafenib
14	M	360	Bone, Retroperitoneal	N	1	3A	17+	Pazopanib, RT, Nivolumab
15	F	381	Bone	Y	2	2A	17+	Pazopanib, RT, Nivolumab
16	F	1241	Lung	N	2	3A	16+	Pazopanib, Nivolumab

Notes:

NA = Not applicable because patients 2 and 11 did not undergo surgery following SBRT.

(+) denotes still alive.

PTV = Planning Target Volume for radiation.

Patients 4 and 8 were removed due to final pathology other than clear cell cancer.